Back to top

vaccines: Archive

Zacks Equity Research

Moderna (MRNA) Stock Outperformed Industry YTD: Here's Why

Shares of Moderna (MRNA) are being driven by encouraging pipeline updates and plans for potential product launches.

MRKPositive Net Change MRNANegative Net Change HRTXPositive Net Change ARQTNegative Net Change

Zacks Equity Research

Pfizer (PFE) Starts Another Cost-Cut Plan to Save $1.5B by 2027

This is the second cost-reduction program undertaken by Pfizer (PFE) in the past year. The first phase of this program is expected to save nearly $1.5 billion by 2027-end.

PFEPositive Net Change HRTXPositive Net Change MRNSNegative Net Change ARQTNegative Net Change

Sundeep Ganoria

Vaccine Stocks Rise on Growing Threat of Bird Flu Infections

The Biden administration is reportedly in talks with vaccine makers Moderna (MRNA) and Pfizer (PFE) to develop bird flu vaccines over increasing fears of widespread transmission of the infection.

PFEPositive Net Change MRNANegative Net Change NVAXNegative Net Change CVACPositive Net Change

Zacks Equity Research

Why Novavax (NVAX) Stock Price Appreciated 14% on Monday

Novavax (NVAX) surges after one of its top shareholders drops a proxy campaign against the company. This withdrawal is in sync with the company???s recently signed multi-billion-dollar deal with Sanofi.

SNYPositive Net Change PFEPositive Net Change MRNANegative Net Change NVAXNegative Net Change

Zacks Equity Research

Novavax (NVAX) Q1 Earnings Miss, Stock Soars on Sanofi Deal

Novavax (NVAX) partners with Sanofi to market its COVID-19 vaccine and also develop novel COVID-19-influenza combination vaccines. This announcement even overshadows the dismal Q1 results.

SNYPositive Net Change PFEPositive Net Change MRNANegative Net Change NVAXNegative Net Change